Exact doubles down on Cologuard, eyes future test development — 4 insights

Exact Sciences is developing 15 diagnostic cancer tests. Exact Sciences' eventual goal is to develop a universal cancer test, the Wisconsin State Journal reports.

What you should know:

1. Exact Sciences CEO Kevin Conroy elaborated on the company's development profile at The J.P. Morgan Healthcare Conference, Jan. 7-10 in San Francisco. Mr. Conroy said, "Ultimately, the goal is to develop a universal cancer screening test so that everybody in this room can get one test every year or every other year to see if they may have cancer."

2. Concerning colonoscopy alternative Cologuard, Exact has made a series of aggressive measures. Exact and Pfizer's October 2018 marketing partnership was already expanded to include obstetricians and gynecologists, increasing exposure.

3. Exact is opening a second laboratory to test Cologuard tests. Once complete, Exact will have the capability to test up to 7 million tests annually.

4. Exact is also developing a new version of Cologuard that is expected to be "even more sensitive" for early colorectal cancer cases.

More articles on supply chain:
Spencer Hospital reopens surgery center after fire — 3 insights
10 ASCs focused on GI & endoscopy
Buying refurbished medical equipment? Ask these 5 Qs first

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months